Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 17/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475536 | 0.89 | DHODH (0.50) | TACR3DHODH | |
| SCHEMBL4668037 | 0.86 | TACR3 (0.53) | TACR3DHODHPLA2G2ASMN1; SMN2 | |
| SCHEMBL5481030 | 0.85 | TACR3 (0.49) | TACR3DHODHPLA2G2AKCNH2 | |
| SCHEMBL4879045 | 0.82 | DHODH (0.71) | TACR3DHODHSMN1; SMN2 | |
| SCHEMBL4895783 | 0.82 | BDKRB1 (0.50) | TACR3DHODHPLA2G2AKCNH2 | |
| SCHEMBL15491395 | 0.81 | TACR3 (0.68) | TACR3DHODH | |
| SCHEMBL14492107 | 0.79 | TACR3 (0.73) | TACR3 | |
| SCHEMBL5476377 | 0.77 | DHODH (0.47) | TACR3DHODH | |
| SCHEMBL5486956 | 0.77 | DHODH (0.58) | TACR3DHODHKCNH2 | |
| SCHEMBL15491402 | 0.74 | DHODH (0.58) | TACR3DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | TACR3, GRIK3, TACR2 | TACR3 1/4885DHODH 3942/4885PLA2G2A 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.